Experience

Nelson Cash

• United States
• Design Services
• 1 - 100 Employee

• Founder

  • 2011 - Present

  We're busy designing new intersections for culture and technology. Nelson Cash is a creative studio with roots in Chicago, New York, and Portland. We believe in fostering relationships with our clients on a simple guiding principle - your project is unique, and unique challenges require unique solutions. Our perspective allows us to strategize wisely, design quickly, and develop holistically from the ground up. www.nelsoncash.com Specialties: Research & Strategy, Branding & Marketing, UX/UI & Visual Design, Website Design & Development, Writing, Photography, Product Development, Packaging, Digital Technology, Data Visualization, Digital Marketing & Advertising Show less



PhoneFive.Me

• Technology, Information and Internet

• Co-Founder

  • 2011 - Jan 2012

  PhoneFive.me is a new marketplace for knowledge and experience. Use PhoneFive to access others' expertise or monetize your mind Phonefive.me PhoneFive.me is a new marketplace for knowledge and experience. Use PhoneFive to access others' expertise or monetize your mind Phonefive.me



Passport Capital

• Consultant

  • Jan 2010 - Aug 2011

• Portfolio Manager

  • Aug 2004 - Dec 2009

  • Healthcare Portfolio Manager for $3B Global Macro Hedge Fund• Focused on US and ex-US healthcare and biological related non-healthcare companies in industrial agricultural, commodity and energy industries• Investment experience in Europe, Eastern Europe, Singapore, Hong Kong, China, India and Australia



Avexa

• Advisory Board Member

  • Jun 2010 - Aug 2010

  Advisory board member Avexa is a Biotechnology company located in Melbourne Australia Advisory board member Avexa is a Biotechnology company located in Melbourne Australia



Castle Creek

• Senior Analyst

  • Jan 1999 - May 2004

  • Primary responsibility included coverage of ~70 healthcare stocks. Sectors included devices, diagnostics, biotechnology, CRO’s, life science tools and medical equipment • Developed risk management infrastructure, constructed detailed financial, product tracking and clinical scoring models, proprietary comparative screening and valuation models for healthcare universe • Primary responsibility included coverage of ~70 healthcare stocks. Sectors included devices, diagnostics, biotechnology, CRO’s, life science tools and medical equipment • Developed risk management infrastructure, constructed detailed financial, product tracking and clinical scoring models, proprietary comparative screening and valuation models for healthcare universe



Kilkenny Capital

• Analyst

  • Sep 1996 - Aug 1999

  • Developed a probability adjusted economic model for evaluating company stock price • Market analysis of therapeutic areas, disease classifications and new technologies including; genomics, pharmacogenomics and monoclonal antibodies • Fundamental and technical analysis of scientific research, product pipelines and market potential • Developed a probability adjusted economic model for evaluating company stock price • Market analysis of therapeutic areas, disease classifications and new technologies including; genomics, pharmacogenomics and monoclonal antibodies • Fundamental and technical analysis of scientific research, product pipelines and market potential



Ann & Robert H. Lurie Children's Hospital of Chicago

• United States
• Hospitals and Health Care
• 700 & Above Employee

• Brain Tumor Program

  • Nov 1996 - Nov 1997

  • Development of comparative gene expression indices used to predict clinical outcomes of primitive neuroectodermal pediatric brain tumors such as Medulloblastomas through Real-Time Quantitative Optical PCR techniques • Quantitatively identified gene expression levels of clinically relevant genes, built indices of these genes vs. housekeeping controls and used this information in the treatment of patients • Development of comparative gene expression indices used to predict clinical outcomes of primitive neuroectodermal pediatric brain tumors such as Medulloblastomas through Real-Time Quantitative Optical PCR techniques • Quantitatively identified gene expression levels of clinically relevant genes, built indices of these genes vs. housekeeping controls and used this information in the treatment of patients